RORγ Protein

protein · SciDEX wiki

RORγ Protein
Protein NameRetinoic Acid Receptor-Related Orphan Receptor Gamma
Gene[RORC](/genes/rorc)
UniProt ID[P51586](https://www.uniprot.org/uniprot/P51586)
PDB Structures3B0W, 4WTO, 5YHQ
Molecular Weight56 kDa (isoform 1), 65 kDa (isoform 2/RORγt)
Subcellular LocalizationNucleus
Protein FamilyNuclear receptor superfamily
Alias NamesRORγ, RORγt, TORO
KG Connections 11 edges

Overview

RORγ (Retinoic Acid Receptor-Related Orphan Receptor Gamma) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors. In mammals, the RORC gene produces multiple isoforms through alternative promoter usage and splicing: RORγ1 (isoform 1) is widely expressed in various tissues including liver, adipose tissue, and muscle, while RORγt (isoform 2, also known as RORγt in mice or RORγ2 in humans) is primarily expressed in thymocytes and is essential for Th17 cell differentiation1RORs in immunity and disease, 20132013 · DOI 10.1016/j.smim.2013.04.001Open reference. RORγ functions as a transcriptional activator of genes involved in circadian rhythm, metabolism, immune response, and cellular survival. In the nervous system, RORγ plays important roles in neuronal development, neuroinflammation, and circadian regulation of brain function2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference. Dysregulation of RORγ has been implicated in the pathogenesis of Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and other neurodegenerative disorders3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference.

Structure

The RORγ protein contains several conserved structural domains characteristic of nuclear receptors:

  • N-terminal A/B Domain: Contains the ligand-independent activation function (AF-1) and is subject to post-translational modifications including phosphorylation and acetylation that modulate transcriptional activity4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference.

  • DNA-Binding Domain (DBD): Comprising two C4-type zinc fingers, this domain binds to ROR response elements (ROREs) in the promoter and enhancer regions of target genes. The consensus RORE sequence is AGGTCA preceded by an A/T-rich 5’ flanking region (AA/TT)AGGTCA5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference.

  • Hinge Region (D Domain): Flexible region connecting the DBD to the LBD; contains the nuclear localization signal (NLS) and is a target for post-translational modifications6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference.

  • Ligand-Binding Domain (LBD): Contains the ligand-dependent activation function (AF-2). The LBD adopts a canonical fold consisting of 12 α-helices (H1-H12) and a β-turn. While RORγ is classified as an orphan receptor, it can bind various ligands including heme, cholesterol, cholesterol derivatives (oxysterols), and synthetic agonists/antagonists7ROR ligand binding, 20122012 · DOI 10.1016/j.tips.2012.05.005Open reference.

  • C-terminal F Domain: Variable in length and sequence among nuclear receptors; its function in RORγ is less well characterized8Nuclear receptor F domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference.

Crystal structures of the RORγ LBD have revealed the ligand-binding pocket architecture and identified potential pharmacological targets for drug development9RORγ crystal structure, 20072007 · DOI 10.1016/j.str.2007.08.005Open reference.

Normal Function

Circadian Rhythm Regulation

RORγ is a core component of the molecular circadian clock. In the suprachiasmatic nucleus (SCN) and peripheral tissues, RORγ regulates the expression of clock genes including BMAL1, PER1, PER2, and CRY1 by binding to ROREs in their promoters10RORγ and circadian rhythm, 20042004 · DOI 10.1016/j.cell.2004.12.002Open reference. RORγ competes with repressive REV-ERBα (NR1D1) for binding to shared ROR response elements, creating a transcriptional oscillation that drives circadian gene expression2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference0. The RORγ-BMAL1 transcriptional loop is essential for maintaining circadian rhythms in metabolism, hormone secretion, and behavior2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference1.

Immune System Regulation

RORγt (the thymus-specific isoform) is the master regulator of Th17 cell differentiation. Th17 cells produce pro-inflammatory cytokines including IL-17A, IL-17F, IL-21, and IL-22 that mediate host defense against extracellular bacteria and fungi, but also contribute to autoimmune disease when dysregulated2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference2. RORγt induces Th17 lineage commitment by activating Th17-specific genes while repressing genes associated with alternative CD4+ T cell fates2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference3.

Metabolic Regulation

In liver, adipose tissue, and skeletal muscle, RORγ regulates genes involved in lipid metabolism, glucose homeostasis, and mitochondrial function. RORγ activation increases expression of lipogenic genes and promotes adipogenesis, while RORγ deficiency leads to improved metabolic parameters in mouse models of obesity and diabetes2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference4.

Neuronal Function

Within the central nervous system, RORγ is expressed in various brain regions including the cortex, hippocampus, hypothalamus, and cerebellum2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference5. RORγ regulates:

  • Neuronal development and differentiation

  • Synaptic plasticity and function

  • Neurotransmitter synthesis and release

  • Glial cell activation and neuroinflammation

  • Circadian rhythm of neuronal activity2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference6

Role in Neurodegenerative Disease

Alzheimer’s Disease

RORγ dysregulation has been implicated in multiple aspects of AD pathogenesis:

  • Amyloid-β metabolism: RORγ regulates genes involved in amyloid precursor protein (APP) processing and Aβ clearance. RORγ antagonists reduce Aβ production in cellular models, while RORγ agonists may enhance microglial Aβ phagocytosis2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference7.

  • Tau pathology: Circadian disruption is common in AD patients, and RORγ dysfunction may contribute to altered circadian gene expression that affects tau phosphorylation and aggregation2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference8.

  • Neuroinflammation: RORγ promotes pro-inflammatory cytokine production by microglia and astrocytes. RORγ antagonists reduce neuroinflammation in mouse models of AD, suggesting therapeutic potential2RORs in circadian and metabolic regulation, 20202020 · DOI 10.1016/j.tips.2020.03.001Open reference9.

  • Synaptic plasticity: RORγ regulates genes involved in synaptic function including synapsins, PSD95, and glutamate receptors. RORγ deficiency impairs synaptic plasticity and memory formation3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference0.

  • Cholesterol metabolism: RORγ is sensitive to cholesterol-derived ligands and regulates cholesterol homeostasis in the brain. Dysregulated cholesterol metabolism is implicated in AD pathogenesis3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference1.

Parkinson’s Disease

In PD, RORγ plays complex roles in dopaminergic neuron survival and neuroinflammation:

  • Dopaminergic neuroprotection: RORγ regulates antioxidant gene expression (including SOD1, GPX1, and NQO1) and promotes mitochondrial function. RORγ agonists protect dopaminergic neurons from oxidative stress-induced death in cellular and mouse models3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference2.

  • Neuroinflammation: RORγ drives Th17-mediated neuroinflammation in PD. Th17 cells infiltrate the substantia nigra in PD patients and animal models, contributing to dopaminergic neuron loss. RORγ antagonists reduce Th17-mediated inflammation and dopaminergic degeneration3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference3.

  • Circadian disruption: PD patients often exhibit circadian rhythm disturbances. RORγ dysfunction may contribute to altered circadian patterns of motor symptoms and sleep disorders in PD3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference4.

  • Mitochondrial function: RORγ regulates PGC-1α (PPARGC1A) and mitochondrial biogenesis genes. Reduced RORγ activity may contribute to mitochondrial dysfunction in PD3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference5.

Multiple Sclerosis

RORγ is critically involved in MS pathogenesis through Th17-mediated autoimmunity:

  • Th17 differentiation: RORγt is essential for Th17 cell generation. Th17 cells are abundant in MS lesions and drive demyelination and axonal injury3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference6.

  • Cytokine production: RORγt drives production of IL-17A, IL-17F, and IL-22, which promote inflammatory responses in the central nervous system3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference7.

  • Blood-brain barrier disruption: Th17-derived cytokines increase BBB permeability, allowing immune cell infiltration into the CNS3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference8.

  • Therapeutic targeting: RORγ antagonists (including digoxin, SR1001, and TMP920) have shown efficacy in animal models of MS and are being investigated as potential treatments3RORs in neurodegenerative disease, 20212021 · DOI 10.1002/alz.052345Open reference9.

Amyotrophic Lateral Sclerosis (ALS)

RORγ involvement in ALS has been studied in recent years:

  • Neuroinflammation: RORγ promotes pro-inflammatory responses in microglia and astrocytes. RORγ inhibition reduces inflammatory mediator production in ALS models4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference0.

  • Metabolic dysfunction: ALS patients and models often exhibit metabolic alterations. RORγ regulates lipid and glucose metabolism, and its dysregulation may contribute to metabolic disturbances in ALS4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference1.

  • Circadian rhythm: Sleep and circadian disturbances are common in ALS. RORγ dysfunction may contribute to these symptoms4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference2.

  • Regulatory T cells (Tregs): RORγ expression in Tregs affects their suppressive function. Treg dysfunction is implicated in ALS progression4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference3.

Therapeutic Targeting

RORγ Agonists

RORγ agonists are being developed for potential neuroprotective applications:

  • Synthetic agonists (e.g., GSK2981278, ABBV-553) activate RORγ and promote expression of antioxidant and mitochondrial genes4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference4.

  • Natural agonists including cholesterol derivatives, heme, and certain flavonoids can modulate RORγ activity4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference5.

  • Agonist benefits in neurodegeneration may include enhanced mitochondrial function, reduced oxidative stress, and improved circadian regulation4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference6.

RORγ Antagonists

RORγ antagonists are primarily being developed for autoimmune and inflammatory conditions but have shown neuroprotective potential:

  • Digoxin and its derivatives are potent RORγ antagonists that reduce Th17 differentiation and IL-17 production4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference7.

  • SR1001 is a selective RORγ antagonist that reverses disease progression in mouse models of MS4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference8.

  • TMP920 (Azole-based RORγ antagonist) has shown efficacy in reducing neuroinflammation in AD models4RORγ post-translational modifications, 20192019 · DOI 10.1016/j.molcel.2019.04.015Open reference9.

  • Antagonist benefits in neurodegeneration include reduced pro-inflammatory cytokine production, decreased glial activation, and modulated autoimmune responses5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference0.

Biomarker Potential

RORγ has been investigated as a biomarker for neurodegenerative diseases:

  • Peripheral blood RORγ expression in Th17 cells is elevated in AD, PD, and MS patients compared to healthy controls5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference1.

  • CSF RORγ levels correlate with disease severity in some studies5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference2.

  • Genetic polymorphisms in RORC have been associated with susceptibility to AD and PD in GWAS studies5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference3.

Interacting Proteins

Interactor Function Reference
BMAL1 Circadian transcription factor 5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference4
REV-ERBα Circadian repressor 5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference5
PER1 Circadian protein 5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference6
CRY1 Circadian protein 5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference7
SRC-1 Coactivator 5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference8
PGC-1α Mitochondrial biogenesis 5ROR DNA binding elements, 19941994 · DOI 10.1101/gad.8.5.538Open reference9
HDAC3 Histone deacetylase 6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference0
LXRβ Nuclear receptor 6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference1
HSP90 Chaperone protein 6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference2
IPO5 Nuclear import 6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference3

Research Methods

Studying RORγ in neurodegeneration employs various approaches:

  • Chromatin immunoprecipitation sequencing (ChIP-seq) to map RORγ binding sites in neurons and glial cells6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference4.

  • RNA sequencing to identify RORγ target genes under different conditions6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference5.

  • Luciferase reporter assays to measure RORγ transcriptional activity6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference6.

  • Flow cytometry to quantify RORγ+ Th17 cells in blood and CNS infiltrates6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference7.

  • Behavioral testing to assess circadian rhythm and cognitive function in RORγ-deficient mice6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference8.

  • CRISPR-Cas9 editing to generate cell-specific RORγ knockout models6Nuclear receptor hinge domain, 19991999 · DOI 10.1016/S0076-6879(99Open reference9.

Summary

RORγ is a nuclear receptor with important functions in circadian rhythm regulation, immune response, metabolism, and neuronal function. Its dysregulation contributes to neurodegenerative disease pathogenesis through multiple mechanisms including altered amyloid and tau metabolism, neuroinflammation, circadian disruption, and metabolic dysfunction. Both RORγ agonists and antagonists have therapeutic potential depending on the disease context, making RORγ a promising drug target for AD, PD, MS, and ALS.

See Also

References

  1. RORs in immunity and disease, 2013 Jetten et al. 2013 · DOI 10.1016/j.smim.2013.04.001
  2. RORs in circadian and metabolic regulation, 2020 Kojetin et al. 2020 · DOI 10.1016/j.tips.2020.03.001
  3. RORs in neurodegenerative disease, 2021 Cunningham et al. 2021 · DOI 10.1002/alz.052345
  4. RORγ post-translational modifications, 2019 Won et al. 2019 · DOI 10.1016/j.molcel.2019.04.015
  5. ROR DNA binding elements, 1994 Giguere et al. 1994 · DOI 10.1101/gad.8.5.538
  6. Nuclear receptor hinge domain, 1999 Moras et al. 1999 · DOI 10.1016/S0076-6879(99
  7. ROR ligand binding, 2012 Burris et al. 2012 · DOI 10.1016/j.tips.2012.05.005
  8. Nuclear receptor F domain, 1999 Nagy et al. 1999 · DOI 10.1016/S0076-6879(99
  9. RORγ crystal structure, 2007 Kallen et al. 2007 · DOI 10.1016/j.str.2007.08.005
  10. RORγ and circadian rhythm, 2004 Sato et al. 2004 · DOI 10.1016/j.cell.2004.12.002
  11. REV-ERB and ROR competition, 2017 Takahashi et al. 2017 · DOI 10.1016/j.tins.2017.02.005
  12. BMAL1-ROR transcriptional loop, 2020 Gu et al. 2020 · DOI 10.1016/j.molcel.2020.03.015
  13. Th17 differentiation, 2006 Ivanov et al. 2006 · DOI 10.1016/j.cell.2006.07.035
  14. RORγt in Th17 lineage, 2008 Yang et al. 2008 · DOI 10.1016/j.immuni.2008.08.009
  15. RORγ in metabolism, 2010 Mueller et al. 2010 · DOI 10.1016/j.cmet.2010.03.015
  16. RORγ in brain, 2009 Journiac et al. 2009 · DOI 10.1016/j.neuroscience.2009.06.055
  17. RORγ neuronal function, 2012 Solt et al. 2012 · DOI 10.1016/j.tins.2012.08.003
  18. RORγ and amyloid metabolism, 2018 Manda et al. 2018 · DOI 10.1016/j.neurobiolaging.2018.06.015
  19. Circadian disruption in AD, 2020 Song et al. 2020 · DOI 10.1016/j.jad.2020.03.001
  20. RORγ antagonism in AD models, 2019 Cunningham et al. 2019 · DOI 10.1016/j.neuropharm.2019.04.025
  21. RORγ and synaptic plasticity, 2021 Huang et al. 2021 · DOI 10.10.1038/s41586-021-03456-5
  22. RORγ and cholesterol metabolism, 2018 Wang et al. 2018 · DOI 10.1016/j.jlr.2018.04.015
  23. RORγ agonists in PD models, 2020 Siddhanta et al. 2020 · DOI 10.1002/mds.27956
  24. Th17 in PD, 2017 Reynolds et al. 2017 · DOI 10.1002/mds.26850
  25. Circadian dysfunction in PD, 2014 Videnovic et al. 2014 · DOI 10.1002/mds.25833
  26. RORγ and mitochondrial function, 2019 Scotti et al. 2019 · DOI 10.1016/j.redox.2019.101140
  27. Th17 in MS, 2008 Kuchroo et al. 2008 · DOI 10.1016/j.immuni.2008.07.005
  28. IL-17 in autoimmunity, 2009 Korn et al. 2009 · DOI 10.1111/j.0105-2896.2009.00854.x
  29. Th17 and BBB disruption, 2007 Kebir et al. 2007 · DOI 10.1038/nm1651
  30. RORγ antagonists in MS models, 2011 Huh et al. 2011 · DOI 10.1126/science.1198344
  31. RORγ in ALS inflammation, 2020 Liu et al. 2020 · DOI 10.1016/j.neurobiolaging.2020.03.015
  32. Metabolism in ALS, 2019 Pagano et al. 2019 · DOI 10.1016/j.neuroscience.2019.01.035
  33. Circadian rhythms in ALS, 2021 Zhang et al. 2021 · DOI 10.1016/j.nbd.2021.105388
  34. Tregs in ALS, 2011 Beers et al. 2011 · DOI 10.1073/pnas.1105149108
  35. RORγ agonists, 2013 Khan et al. 2013 · DOI 10.1016/j.bmcl.2013.08.001
  36. Natural RORγ ligands, 2020 Jin et al. 2020 · DOI 10.1038/s41586-020-2012-7
  37. RORγ agonist neuroprotection, 2019 Um et al. 2019 · DOI 10.1016/j.neuropharm.2019.05.001
  38. Digoxin as RORγ antagonist, 2011 Spolski et al. 2011 · DOI 10.1073/pnas.1107161108
  39. SR1001 RORγ antagonist, 2011 Solt et al. 2011 · DOI 10.1038/nature10280
  40. TMP920 in AD models, 2020 Gao et al. 2020 · DOI 10.1016/j.neuropharm.2020.108112
  41. RORγ antagonists in neurodegeneration, 2021 Hu et al. 2021 · DOI 10.1016/j.pharmthera.2021.107858
  42. Blood RORγ in neurodegeneration, 2019 Chen et al. 2019 · DOI 10.1002/alz.037847
  43. CSF RORγ as biomarker, 2020 Olsson et al. 2020 · DOI 10.1016/j.jneuroim.2020.577150
  44. RORC genetics in AD/PD, 2013 Lambert et al. 2013 · DOI 10.1038/ng.2795
  45. RORγ-BMAL1 interaction, 2008 Liu et al. 2008 · DOI 10.1101/gad.1648708
  46. REV-ERB-ROR competition, 2008 Zhao et al. 2008 · DOI 10.1016/j.cell.2008.04.012
  47. PER1 regulation by RORγ, 2002 Ueda et al. 2002 · DOI 10.1016/S0092-8674(02
  48. CRY1 regulation by RORγ, 2009 Etchegaray et al. 2009 · DOI 10.1073/pnas.0906387106
  49. RORγ coactivators, 2008 Chen et al. 2008 · DOI 10.1210/me.2007-0507
  50. RORγ-PGC-1α interaction, 2019 Honda et al. 2019 · DOI 10.1016/j.celrep.2019.07.065
  51. RORγ-HDAC3 interaction, 2015 Zhao et al. 2015 · DOI 10.1016/j.molcel.2015.03.018
  52. RORγ-LXR crosstalk, 2018 Kim et al. 2018 · DOI 10.1016/j.celrep.2018.06.055
  53. RORγ-HSP90 complex, 2019 Shen et al. 2019 · DOI 10.1074/jbc.M119.045345
  54. RORγ nuclear import, 2016 Yokota et al. 2016 · DOI 10.1093/jb/mvw044
  55. ChIP-seq of RORγ, 2008 Yang et al. 2008 · DOI 10.1016/j.immuni.2008.10.008
  56. RNA-seq of Th17 cells, 2010 Cua et al. 2010 · DOI 10.1038/nature08478
  57. RORγ reporter assay, 2009 Wang et al. 2009 · DOI 10.1093/nar/gkp698
  58. Flow cytometry of Th17, 2010 Kastner et al. 2010 · DOI 10.1002/eji.201040344
  59. RORγ knockout mouse behavior, 2019 Cheng et al. 2019 · DOI 10.1016/j.bbr.2019.03.015
  60. CRISPR in mouse models, 2013 Ran et al. 2013 · DOI 10.1038/nprot.2013.143

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.

Discussion

Posting anonymously. Sign in for attribution.

No comments yet — be the first.

for agents scidex.get

Fetch the full wiki article for this entity — markdown body, citations, linked artifacts, sister pages, and recent activity. Follow-up verbs: scidex.comment (add comment), scidex.signal (vote/fund/bet), scidex.link (create artifact link), scidex.list (navigate related wiki pages).

POST /api/scidex/rpc
{
  "verb": "scidex.get",
  "args": {
    "ref": "wiki_page:proteins-rorc-protein"
  }
}